Caprion Proteomics, Inc.
Caprion Proteomics is the leading provider of proteomics based
services to the pharmaceutical industry.
Caprion’s proprietary proteomics discovery technology, CellCarta®,
is a gel-free, label-free mass spectrometry platform that enables a
comprehensive, quantitative and robust measurement of the protein
expression differences across large sets of biological samples.
Caprion has been providing biomarker and target identification
services since 2002, and has served such clients as Pfizer, Johnson
& Johnson, Abbott Laboratories, Biogen Idec, Daiichi-Sankyo,
Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim,
Schering , EMD-Serono, Vertex, DebioPharm and Transgene. Caprion
also has been awarded two major 5-year Biodefense proteomics
research contracts in infectious disease with the NIH-NIAID, and was
awarded the Frost & Sullivan Biomarker Technology award in 2007.